Independent Advisor Alliance Invests $352,000 in Zoetis Inc. (NYSE:ZTS)

Independent Advisor Alliance acquired a new position in Zoetis Inc. (NYSE:ZTS) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,115 shares of the company’s stock, valued at approximately $352,000.

Several other institutional investors have also recently made changes to their positions in ZTS. Fairfield Bush & CO. bought a new position in shares of Zoetis in the first quarter worth about $134,000. Sequoia Financial Advisors LLC raised its position in shares of Zoetis by 5.3% during the 1st quarter. Sequoia Financial Advisors LLC now owns 4,166 shares of the company’s stock valued at $786,000 after purchasing an additional 211 shares during the period. Candriam Luxembourg S.C.A. raised its position in shares of Zoetis by 3.9% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 51,581 shares of the company’s stock valued at $9,727,000 after purchasing an additional 1,914 shares during the period. Covestor Ltd raised its position in shares of Zoetis by 102.8% during the 1st quarter. Covestor Ltd now owns 724 shares of the company’s stock valued at $137,000 after purchasing an additional 367 shares during the period. Finally, Merit Financial Group LLC raised its position in shares of Zoetis by 92.8% during the 1st quarter. Merit Financial Group LLC now owns 2,342 shares of the company’s stock valued at $442,000 after purchasing an additional 1,127 shares during the period. Institutional investors own 89.47% of the company’s stock.

Zoetis Trading Down 1.1 %

ZTS opened at $190.43 on Wednesday. The firm has a market cap of $87.66 billion, a P/E ratio of 40.01, a P/E/G ratio of 3.10 and a beta of 0.78. Zoetis Inc. has a 12 month low of $124.15 and a 12 month high of $194.99. The company has a current ratio of 3.50, a quick ratio of 1.97 and a debt-to-equity ratio of 1.42. The stock has a 50-day moving average of $181.24 and a 200 day moving average of $174.34.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 8th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.31 by $0.10. The company had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.16 billion. Zoetis had a return on equity of 52.02% and a net margin of 26.92%. The firm’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted $1.20 earnings per share. As a group, research analysts forecast that Zoetis Inc. will post 5.42 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Piper Sandler raised their price objective on shares of Zoetis from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Monday, August 14th. The Goldman Sachs Group boosted their price target on Zoetis from $204.00 to $213.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Saturday. Stifel Nicolaus boosted their price target on shares of Zoetis from $195.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, August 28th. Finally, HSBC started coverage on shares of Zoetis in a research note on Wednesday. They issued a “buy” rating and a $230.00 price target on the stock. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $225.13.

Insiders Place Their Bets

In other Zoetis news, EVP Robert J. Polzer sold 1,179 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $189.94, for a total transaction of $223,939.26. Following the completion of the transaction, the executive vice president now owns 2,353 shares in the company, valued at $446,928.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Kristin C. Peck sold 13,000 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total transaction of $2,339,610.00. Following the completion of the sale, the chief executive officer now directly owns 56,843 shares of the company’s stock, valued at $10,230,034.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert J. Polzer sold 1,179 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $189.94, for a total transaction of $223,939.26. Following the sale, the executive vice president now directly owns 2,353 shares of the company’s stock, valued at $446,928.82. The disclosure for this sale can be found here. Insiders sold 15,102 shares of company stock valued at $2,741,661 over the last three months. 0.15% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.